Form 4: Intra-Cellular Therapies Director Reports Stock Transaction
SEC Filing
Robert L. Van Nostrand, a director at Intra-Cellular Therapies, Inc., reported the vesting and subsequent disposal of restricted stock units on June 23, 2024.
Summary
- On June 25, 2024, a Form 4 filing was submitted to the SEC by Lawrence J. Hineline, Attorney-in-fact, on behalf of Robert L. Van Nostrand, a director of Intra-Cellular Therapies, Inc.
- The filing reports a transaction that occurred on June 23, 2024, involving common stock.
- Specifically, 1,567 restricted stock units vested and were subsequently disposed of.
- These units, granted on June 23, 2023, vested on the first anniversary of the grant date.
- Following the reported transaction, the director still beneficially owns 11,257 shares of common stock.
Sentiment
Score: 5
Explanation: This is a neutral report of a standard transaction. It doesn't indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and is a normal part of corporate governance.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine vesting and disposal of restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 06/23/2023 | Reporting person was granted 1,567 restricted stock units |
| 06/23/2024 | Restricted stock units vested and were disposed of |
| 06/25/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.